Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06266338 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Primary completion date: Oct 31, 2025 to Oct 31, 2026 Completion date: Oct 31, 2026 to Oct 31, 2027v4 Show 1 more changeShow less
    • Completion date: Oct 31, 2026 to Oct 31, 2027
  3. Re-verified, no change to tracked fieldsv3
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Apr 1, 2024 to Mar 11, 2024 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Apr 1, 2024 to Mar 11, 2024
    • Site details revised
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The main purpose of this study is to gather information about an investigational drug combination, Lenvatinib in combination with pembrolizumab, that may help to treat cervical cancers. In this study, we are looking to see whether the combination of lenvatinib and pembrolizumab has any effect on slowing tumor growth in cervical cancer tumors.
Trial Details
NCT Number NCT06266338
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: Merck Sharp & Dohme LLC
Conditions Cervix Cancer, Cervical Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov